Publications in collaboration with researchers from Hospital General Universitario Gregorio Marañón (32)

2023

  1. Correction: Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era (Bone Marrow Transplantation, (2023), 58, 6, (673-679), 10.1038/s41409-023-01949-x)

    Bone Marrow Transplantation

  2. Role of allogeneic hematopoietic cell transplant for relapsed/refractory aggressive B-cell lymphomas in the CART era

    Bone Marrow Transplantation, Vol. 58, Núm. 6, pp. 673-679

2022

  1. Allogeneic Hematopoietic Stem Cell Transplantation in Transformed Follicular Lymphoma (tFL): Results of a Retrospective Multicenter Study from GELTAMO/GETH-TC Spanish Groups

    Cancers, Vol. 14, Núm. 22

  2. Allogeneic Stem Cell Transplantation in Mantle Cell Lymphoma; Insights into Its Potential Role in the Era of New Immunotherapeutic and Targeted Therapies: The GETH/GELTAMO Experience

    Cancers, Vol. 14, Núm. 11

  3. Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study

    Haematologica, Vol. 107, Núm. 11, pp. 2675-2684

2021

  1. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers

    Transplantation and Cellular Therapy, Vol. 27, Núm. 6, pp. 493.e1-493.e8

  2. Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study

    Bone Marrow Transplantation, Vol. 56, Núm. 8, pp. 1919-1928

  3. Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors

    Bone Marrow Transplantation

  4. Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

    Bone Marrow Transplantation, Vol. 56, Núm. 2, pp. 481-491

2020

  1. RELINF: prospective epidemiological registry of lymphoid neoplasms in Spain. A project from the GELTAMO group

    Annals of Hematology, Vol. 99, Núm. 4, pp. 799-808

2019

  1. Bendamustine as part of conditioning of autologous stem cell transplantation in patients with aggressive lymphoma: a phase 2 study from the GELTAMO group

    British Journal of Haematology, Vol. 184, Núm. 5, pp. 797-807

2017

  1. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

  2. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial

    Biology of Blood and Marrow Transplantation, Vol. 23, Núm. 1, pp. 53-59

2015

  1. Fungal and viral infections after allogeneic hematopoietic transplantation from unrelated donors in adults: Improving outcomes over time

    Bone Marrow Transplantation, Vol. 50, Núm. 2, pp. 274-281

2014

  1. Simplification of risk stratification for splenic marginal zone lymphoma: A point-based score for practical use

    Leukemia and Lymphoma

2013

  1. Phase II clinical trial for the evaluation of bortezomib within the reduced intensity conditioning regimen (RIC) and post-allogeneic transplantation for high-risk myeloma patients

    British Journal of Haematology, Vol. 162, Núm. 4, pp. 474-482

2012

  1. Risk stratification for Splenic Marginal Zone Lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: Development and validation on 593 cases

    British Journal of Haematology, Vol. 159, Núm. 2, pp. 164-171

2011

  1. Long-term results of fludarabine/melphalan as a reduced-intensity conditioning regimen in mantle cell lymphoma: The GELTAMO experience

    Therapeutic Advances in Hematology, Vol. 2, Núm. 1, pp. 5-10

2010

  1. Reduced intensity conditioning HLA identical sibling donor allogeneic stem cell transplantation for patients with follicular lymphoma: Long-term follow-up from two prospective multicenter trials

    Haematologica, Vol. 95, Núm. 7, pp. 1176-1182

  2. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia

    Annals of Hematology, Vol. 89, Núm. 11, pp. 1073-1080